Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, for the ACCESS Study Group, Pierre‐François Laterre et al.|JAMA|2013Cited by 797
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*Mark Tidswell, Steven M. Opal, William Tillis et al.|Critical Care Medicine|2009Cited by 226
Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung InjuryKathleen D. Liu, Michael A. Matthay, Ann Weinacker et al.|American Journal of Respiratory and Critical Care Medicine|2008Cited by 210
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)Jatin Patel, Mark Layton, Damon Bass et al.|European Respiratory Journal|2022Cited by 42
A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR)Jatin Patel, Mark Layton, Albertus Beishuizen et al.|medRxiv|2021Cited by 27